Notizie AIOM – anno XIV n. 589
A Firenze il 2° appuntamento internazionale RIMOG: Oncologia geriatrica, in aumento i casi di pazienti oncologici over 65
“Gli over 65 rappresentano oggi il 20,8% della popolazione italiana ma questa percentuale, entro il 2030, è destinata a salire fino al 26,5% - afferma il Professor Guido Francini, Honorary President della manifestazione. - Se si combina tale dato con quello ...Leggi tutto
Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer screening among family physicians
The results of the National Lung Screening Trial showed a 20% reduction in lung cancer mortality and a 6.7% reduction in all-cause mortality when high-risk patients were screened with low-dose computed tomography (LDCT) versus chest x-ray (CXR). The US Preventive Services ...Leggi tutto
Adjuvant Chemotherapy for Patients with T2N0M0 Non-small-cell Lung Cancer (NSCLC)
Adjuvant chemotherapy improves survival in patients with completely resected stage II and III non-small cell lung cancer (NSCLC). However, its role in patients with stage IB disease remains unclear. We evaluated the role of adjuvant chemotherapy in a large dataset of patients ...Leggi tutto
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis
The impact of a biomarker-based (personalized) cancer treatment strategy in the setting of phase 1 clinical trials was analyzed. To compare patient outcomes in phase 1 studies that used a biomarker selection strategy with those that did not. PubMed search of phase 1 cancer ...Leggi tutto
Stepped Care Targeting Psychological Distress in Head and Neck Cancer and Lung Cancer Patients: a Randomized Controlled Trial
This study aimed to evaluate the efficacy of stepped care (SC) targeting psychological distress in head and neck cancer (HNC) and lung cancer (LC) patients. Patients with untreated distress (Hospital Anxiety and Depression Scale (HADS; HADS-D>7, HADS-A>7, or HADS-total>14)) ...Leggi tutto
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
In the phase 3 CheckMate 025 study, previously treated patients with advanced renal cell carcinoma who were randomly assigned to nivolumab had an overall survival benefit compared with those assigned to everolimus. We aimed to compare health-related quality of life (HRQoL) ...Leggi tutto